On January 13, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) issued the share repurchase plan of the company. According to the announcement, it is planned to use its own funds to repurchase some public shares of the company in the form of centralized bidding transaction. The repurchase price will not exceed 400.00 yuan / share, and the total repurchase funds will be 1 billion yuan.
According to Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) announcement, based on the upper limit of the repurchase price of 400.00 yuan / share and the repurchase amount of 1 billion yuan, the number of repurchases is expected to be 2.5 million shares, accounting for 0.2056% of the current total share capital of the company. The specific number of shares to be repurchased shall be subject to the actual number of shares to be repurchased at the end of the repurchase; The repurchase period shall not exceed 12 months from the date when the board of directors deliberates and approves the share repurchase plan.
Li Xiting, chairman of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) told reporters that the repurchase is precisely because he is firmly optimistic about the future development of the company and continues to be optimistic about the long-term value of Mindray. The ecology of China’s medical device industry is gradually prosperous, and the industry also has many new opportunities for development. While China’s medical devices are going to the world, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) will also continue to explore, actively carry out technical breakthrough, contribute to the development of China’s medical device industry, and become a world leading medical device company.
In response to the recent online news that ” Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) sales staff left their jobs, their performance did not meet expectations, and the inspection production line of Shanghai branch could not complete the task”, Li Xiting said that this rumor was sheer nonsense. In 2021, Mindray’s overall business performance is good and its personnel are stable. The performance of Shanghai Branch grew well in 2021, with the completion of sales tasks exceeding 100%, a year-on-year increase of 46%, and the inspection line increased by 53%.
It is reported that this repurchase is another RMB 1 billion repurchase conducted by Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) after September 2021. Industry insiders said that the company’s management was full of confidence in the company’s future development by spending 1 billion yuan on repurchase twice within half a year. Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) is expected to seize the opportunity of the times and realize long-term and steady development.
Looking forward to 2022, Li Xiting said that Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) main businesses grew steadily, and emerging businesses continued to grow at a high speed. Specifically, there are four important directions worthy of attention: first, from the perspective of production line, the growth of IVD business is accelerated, the promotion of four pillar new products of blood cell, biochemistry, luminescence and coagulation is accelerated, the installation target is improved, the international breakthrough of reagent business is made, and the reagent sales are gradually increased. Benefiting from the new wave of medical infrastructure and the recovery of conventional procurement around the world, the growth of life information and support business will be accelerated. With the company’s continuous breakthrough in the field of high-end technology, the medical imaging business will also achieve good growth, in which the growth of high-end products will be further accelerated.
Secondly, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) will continue to support new medical infrastructure around the world. With excellent product performance, perfect multi product solutions and SanRui IT solutions, it will seize good growth opportunities, continue to achieve breakthrough and penetration of high-end hospitals, and expand brand influence.
In addition, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) orthopedics and IVD products benefited from the impact of centralized procurement, DRGs and other policies in some regions, accelerating the improvement of market coverage and share.
Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) will also increase R & D investment in emerging businesses such as animal medicine, minimally invasive surgery, AED and orthopedics, accelerate the listing of new products and continue to achieve rapid growth.
